Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 314

1.

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

Frieder J, Kivelevitch D, Menter A.

Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16. Review.

2.

The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.

Frieder J, Kivelevitch D, Fiore CT, Saad S, Menter A.

Expert Rev Clin Immunol. 2018 Jan;14(1):1-19. doi: 10.1080/1744666X.2018.1401468. Epub 2017 Nov 22.

PMID:
29110556
3.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A.

J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 2017 Nov 6.

4.

A congenital naevus in a blaschkoid distribution.

Michel P, Menter A, Griffin J.

Clin Exp Dermatol. 2018 Mar;43(2):216-218. doi: 10.1111/ced.13255. Epub 2017 Oct 23. No abstract available.

PMID:
29058330
5.

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C.

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22. No abstract available.

PMID:
28991372
6.

Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.

Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A.

Clin Pharmacol Ther. 2018 Jan;103(1):88-101. doi: 10.1002/cpt.893. Epub 2017 Oct 19. Review.

PMID:
28960267
7.

A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.

Roostaeyan O, Kivelevitch D, Menter A.

Immunotherapy. 2017 Sep;9(12):963-978. doi: 10.2217/imt-2017-0077. Epub 2017 Sep 7.

PMID:
28879789
8.

Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.

Menter A, Thaçi D, Wu JJ, Abramovits W, Kerdel F, Arikan D, Guo D, Ganguli A, Bereswill M, Camez A, Valdecantos WC.

Dermatol Ther (Heidelb). 2017 Sep;7(3):365-381. doi: 10.1007/s13555-017-0198-x. Epub 2017 Aug 16.

9.

The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis.

Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, Guenther L, Sullivan J, Meeuwis K, See K, Duffin KC.

J Drugs Dermatol. 2017 Aug 1;16(8):793-799.

PMID:
28809994
10.

Coronary Plaque Characterization in Psoriasis.

Kivelevitch D, Schussler JM, Menter A.

Circulation. 2017 Jul 18;136(3):277-280. doi: 10.1161/CIRCULATIONAHA.117.029126. No abstract available.

PMID:
28716831
11.

Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.

Frieder J, Kivelevitch D, Menter A.

Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29.

PMID:
28659016
12.

Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Shear NH, Alhusayen R, Fernandez-Obregon A, Kimball AB, Menter A, Wu JJ, Goyal K, Patel H, Lin R, Armstrong AW.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):e544-e547. doi: 10.1111/jdv.14414. Epub 2017 Jul 12. No abstract available.

PMID:
28622413
13.

Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.

Paul C, Leonardi C, Menter A, Reich K, Gold LS, Warren RB, Møller A, Lebwohl M.

Am J Clin Dermatol. 2017 Aug;18(4):591. doi: 10.1007/s40257-017-0295-8. No abstract available.

PMID:
28540589
14.
15.

Adalimumab in paediatric psoriasis.

Kivelevitch D, Menter A.

Lancet. 2017 Jul 1;390(10089):5-6. doi: 10.1016/S0140-6736(17)31190-X. Epub 2017 May 4. No abstract available.

PMID:
28478969
16.

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ.

N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.

17.

Prevalence of psoriasis in Brazil - a geographical survey.

Romiti R, Amone M, Menter A, Miot HA.

Int J Dermatol. 2017 Aug;56(8):e167-e168. doi: 10.1111/ijd.13604. Epub 2017 Mar 27. No abstract available.

PMID:
28345141
18.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26.

PMID:
28322474
19.
20.

Quality of life instruments in psoriasis clinical trials.

Kivelevitch D, Michel P, Menter A.

Br J Dermatol. 2017 Mar;176(3):563. doi: 10.1111/bjd.15102. No abstract available.

PMID:
28300302

Supplemental Content

Loading ...
Support Center